Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Clinical trial NCT05321147 · COMPLETED
Trial details
- NCT number
- NCT05321147
- Sponsor
- Innate Pharma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-17
- Primary completion
- 2023-11-19
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.